The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The game-changing drug, Truvada – the only drug approved for PrEP – will be offered to groups considered at risk of HIV.
Despite a willingness of men to undergo voluntary medical male circumcision (VMMC) for HIV prevention benefits in sub-Saharan Africa, uptake is low with just 56% of the 20.8 million circumcisions by 2016 target met.
The European Commission has given pharmaceutical company, Gilead, the green light to market Truvada as pre-exposure prophylaxis (PrEP) across the region.
An updated adherence analysis from the ASPIRE study indicates that consistent users of a vaginal ring containing dapivirine experienced 65% fewer infections, the 21st International AIDS Conference in Durban, South Africa heard last month.
Heightened concerns regarding the link between the hormonal contraceptive, Depo-Provera, and the risk of HIV acquisition in women after new systematic review released.
UNAIDS has raised the alarm on new HIV infections among adults and the need to step up prevention efforts with 1.9 million adults becoming infected with HIV globally each year since 2010.
The Australian Federation of AIDS Organisations this week declared that AIDS is no longer a public health issue in Australia. In contrast HIV remains a high concern, with no decline in the number of new HIV transmissions for the past decade.
Thailand has become the first country in Asia to eliminnate mother-to-child transmission, meaning the rate of transmission has fallen below 2%.
A qualitative study of women in Malawi who chose not to take HIV treatment as part of the country’s Option B+ programme, or who interrupted their treatment, has found that needing more time to think, concerns about partner support, and side-effects were important reasons for declining to take HIV treatment.
